Marks third Rare Pediatric Drug Designation granted by FDA for pipeline candidate HOUSTON--(BUSINESS WIRE)--IPS HEART, a privately held cell therapy company advancing its stem cell platform to develop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results